Clinton Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Clinton Group’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,238	Closed	-$261K	–	719
2017 Q1	$261K	Buy	+18,238	New	+$249K	0.02%	805

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Clinton Group's IRWD Position: Q2 2017 in Review

Clinton Group sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2017, closing a stake of 18,238 shares — an estimated $261K sold.

Clinton Group first reported a position in IRWD in Q1 2017 and held it in 1 quarter. The position peaked at $261K in Q1 2017. 167 funds tracked by Wall St. Rank hold IRWD as of Q2 2017.

Clinton Group reported no remaining Ironwood Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Clinton Group sold 18,238 Ironwood Pharmaceuticals shares in Q2 2017, an estimated $261K.
Clinton Group first reported a position in Ironwood Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Clinton Group's Ironwood Pharmaceuticals position peaked at $261K in Q1 2017.
167 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.